Attachments:
FileDescriptionFile size
Download this file (HTL June 2017 Investor Presentations-Final.pdf)20-June-2017-Press-Release.pdfHamilton Thorne to Present to Investors in Toronto on June 27 and in Montreal on June 2822 kB

HAMILTON THORNE TO PRESENT TO INVESTORS IN TORONTO ON JUNE 27 AND IN MONTREAL ON JUNE 28

BEVERLY, MA and TORONTO, Ontario – June 20, 2017 - Hamilton Thorne Ltd. (TSX-V: HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will be presenting to investors at The MicroCap Conference in Toronto on June 27 and at the Espace MicroCap quarterly meeting in Montreal on June 28.

Toronto June 27, 2017 - David Wolf, President and CEO of Hamilton Thorne will be presenting to investors at The MicroCap Conference at the Sheraton Centre Hotel in Toronto on Tuesday, June 27 at 10:00 am and will be available for one-on-one meetings with the investment community during the day of the event.

Montreal June 28, 2017 - Mr. Wolf will also be presenting to investors at the Espace MicroCap quarterly 5to7 Cocktail meeting at the Bier Markt Montreal on Wednesday, June 28 at approximately 6:00 pm.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics. Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.    
978-921-2050 
ir [AT] hamiltonthorne [DOT] com
Michael Bruns, CFO
Hamilton Thorne Ltd. 
978-921-2050    
ir [AT] hamiltonthorne [DOT] com

Subscribe to Our Investor Email List